These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 25176981)
41. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Mikhael JR; Schuster SR; Jimenez-Zepeda VH; Bello N; Spong J; Reeder CB; Stewart AK; Bergsagel PL; Fonseca R Blood; 2012 May; 119(19):4391-4. PubMed ID: 22331188 [TBL] [Abstract][Full Text] [Related]
42. Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease. Tovar N; Cibeira MT; Rosiñol L; Solé M; de Larrea CF; Escoda L; Rovira M; Bladé J Eur J Haematol; 2012 Oct; 89(4):340-4. PubMed ID: 22690902 [TBL] [Abstract][Full Text] [Related]
43. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Venner CP; Gillmore JD; Sachchithanantham S; Mahmood S; Lane T; Foard D; Rannigan L; Gibbs SD; Pinney JH; Whelan CJ; Lachmann HJ; Hawkins PN; Wechalekar AD Leukemia; 2014 Dec; 28(12):2304-10. PubMed ID: 25027514 [TBL] [Abstract][Full Text] [Related]
44. [Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement]. Pika T; Lochman P; Vymětal J; Metelka R; Minařík J; Látalová P; Zapletalová J; Bačovský J; Ščudla V Klin Onkol; 2013; 26(5):343-7. PubMed ID: 24107157 [TBL] [Abstract][Full Text] [Related]
45. [Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens]. Adam Z; Stork M; Pour L; Krejčí M; Zahradová L; Sandecká V; Hájek R; Cermáková Z; Pospíšilová Y; Navrátil M; Král Z; Mayer J Vnitr Lek; 2012 Dec; 58(12):896-903. PubMed ID: 23427947 [TBL] [Abstract][Full Text] [Related]
46. Jejunal amyloidosis: a rare cause of severe gastrointestinal bleeding. Yau AH; Cornell IS; Cheung J Can J Gastroenterol; 2012 Jun; 26(6):320-1. PubMed ID: 22720270 [No Abstract] [Full Text] [Related]
47. Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis. Le Bras F; Molinier-Frenkel V; Guellich A; Dupuis J; Belhadj K; Guendouz S; Ayad K; Colombat M; Benhaiem N; Tissot CM; Hulin A; Jaccard A; Damy T Eur J Cancer; 2017 May; 76():183-187. PubMed ID: 28334621 [TBL] [Abstract][Full Text] [Related]
48. Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy. Sher T; Hayman SR; Gertz MA Clin Adv Hematol Oncol; 2012 Oct; 10(10):644-51. PubMed ID: 23187770 [TBL] [Abstract][Full Text] [Related]
49. Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib. Kastritis E; Gavriatopoulou M; Roussou M; Fotiou D; Ziogas DC; Migkou M; Eleutherakis-Papaiakovou E; Panagiotidis I; Kanellias N; Psimenou E; Papadopoulou E; Pamboucas C; Manios E; Gakiopoulou H; Ntalianis A; Tasidou A; Giannouli S; Terpos E; Dimopoulos MA Blood Cancer J; 2017 Jun; 7(6):e570. PubMed ID: 28622303 [TBL] [Abstract][Full Text] [Related]
50. Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. Fett NM; Toporcer MB; Dalmau J; Shinohara MM; Vogl DT Am J Hematol; 2011 Oct; 86(10):893-6. PubMed ID: 22026006 [No Abstract] [Full Text] [Related]
52. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients. Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726 [TBL] [Abstract][Full Text] [Related]